Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study
Andrew J. Burger(Beth Israel Deaconess Medical Center), Uri Elkayam(Icahn School of Medicine at Mount Sinai), Thierry H. LeJemtel(Tulane University), George W. Dennish, Guillermo Torre‐Amione(Baylor College of Medicine), Jay Dinerman(Harvard University Press), Michael Koren(Harvard University Press), Mei Cheng(Pharmacyclics (United States)), Marc A. Silver(Banner - University Medical Center Phoenix), Darlene P. Horton(Scion), Jalal K. Ghali(Launchpad Central (United States))
Cited by 323
Related Papers
Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
|American Heart Journal|2005|2.1k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Peripartum Cardiomyopathy: A Position Statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy
|European Journal of Heart Failure|2010|1.1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies
|New England Journal of Medicine|2016|597